Table 1:

Characteristics of included studies.

	Author	Enrollment Years	Design	Stage (TNM)	Groups	N of Patients	Male%	Age2	RT dose (Gy)	CT regimen	Interval Period7	Treatment Compliance%8
Washington Cohort	Markovina et al. (2017)	2009-2012	P II	cT3-4 N0-2 M0	Study	69	71	57.2	25	mFOLFOX-6 (4 cycles)	11-17	96.7
					Control	69	67	56.6	45	5FU or capecitabine	6-8	100
	Myerson et al. (2014)	2009-2012	P II (single arm)	cT3-4 N0-2 M0-1	Study	76	71	56.43	25	mFOLFOX-6 (4 cycles)	11-17	56
					Control
Polish Cohort	Ciseł et al. (2019)	2008-2014	P III	cT3-4 N0-2	Study	261	70	60	25	FOLFOX-4 (3 cycles)	12	NR
					Control	254	67	60	50.4	5FU+Leucovorin plus Oxaliplatin (2 cycles)4	6	NR
	Bujko et al. (2016)	2008-2014	P III	cT3-4 N0-2	Study	261	70	60	25	FOLFOX-4 (3 cycles)	12	63
					Control	254	67	60	50.4	5FU+Leucovorin plus Oxaliplatin (2 cycles)4	6	66
	Bujko et al. (2013)	2008-2010	P III	cT3-4 N0-2	Study	49	67	60	25	FOLFOX-4 (3 cycles)	12	73.5
					Control	48	69	59	50.4	5FU+Leucovorin plus Oxaliplatin (2 cycles)	6	72.9
Iranian Cohort	Aghili et al. (2020)	2016-2020	RCT	cT3-4 N0-2 M0	Study	33	55	56	25	concurrent XELOX; Consolidative XELOX (3-4 cycles)	15-20	87.9
					Control	27	63	53	50-50.4	concurrent Capecitabine; Consolidative XELOX (3-4 cycles)	15-20	81.8
	Aghili et al. (2018)	2013-2015	P II (single arm)	cT3-4 N0-2 M0	Study	33	73	61	25	concurrent XELOX; Consolidative XELOX (1 cycle)	7-9	87.9
					Control
Baltimore Cohort	Jia et al. (2019)	2017-2019	R	cT2-4 N0-2	Study	26	77	52	25	mFOLFOX-6 (25 patients), CapeOX (1 patient)5	14.5	81
					Control
Danish Cohort	Van Dijk et al. (2013)	2006-2010	P II (single arm)	cT2-4 N0-2 M1	Study	50	54	59	25	CapeOX-Bevacizumab (6 cycles)	26	84
					Control
RAPIDO trial	Bahadoer et al. (2020)	2011-2016	P III	cT2-4 N0-2 M0	Study	462	65	62	25	CapeOX (6 cycles) or FOLFOX4 (9 cycles)6	24	85
					Control	450	69	62	50.4 or 50*	Capecitabine	6-10	90
Indian Cohort	Thakur et al. (2020) 1	2015-2016	Prospective	NR	Study	14	NR	NR	25	CapeOX (2 cycles)	11-13	100
					Control	13	NR	NR	45	Capecitabine	4-6	87

(RCT = randomized clinical trial; P II/III = phase II/III; R = retrospective cohort, Pr = prospective cohort, N = number, NR = not reported, RT = radiotherapy; CT = chemotherapy; FOLFOX = fluorouracil, leucovorin, and oxaliplatin; 5FU = fluorouracil; XELOX/CapeOX = capecitabine and oxaliplatin)

¹Specific data on CRC stages, Male% and Age were not reported (NR) by Thakur et al., however, the authors state that the study and control groups were comparable in these regards.

²Median Age reported in years.

³Mean Age reported in years.

⁴Oxaliplatin delivery left to local institution’s discretion after 2012.

⁵Number of chemotherapy cycles were left at the treating physician’s discretion

⁶Either chemotherapy regimen was used depending on the decision of the treating physician and hospital policy

⁷Approximate intervals between completion of radiotherapy (SCRT or LCRT) and Surgery (in weeks)

⁸Based on need for dose reduction and/or treatment delay due to toxicity or the proportion of patients completing the entire intended treatment